Acer Medical (ROCO:6857) Piotroski F-Score: 4 (As of Jul. 02, 2026) — Near Median


ROCO:6857 Acer Medical Inc ROCO:6857
52 GF Score
Price NT$93.00
GF Value NT$262.01
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Acer Medical Piotroski F-Score?

Acer Medical ROCO:6857 -0.96% 52 Piotroski F-Score is 4 as of Jul. 02, 2026, which is at its 10-year median of 4.00. GuruFocus rates ROCO:6857 with a GF Score™ of 52/100 and a GF Value™ of NT$262.01 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 651 Healthcare Providers & Services companies, Acer Medical ranks worse than 67.59% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Acer Medical has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Acer Medical's Piotroski F-Score or its related term are showing as below:

ROCO:6857' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 7
Current: 4

During the past 7 years, the highest Piotroski F-Score of Acer Medical was 7. The lowest was 2. And the median was 4.

Acer Medical  (ROCO:6857) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Acer Medical Piotroski F-Score Related Terms


Acer Medical Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Acer Medical's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acer Medical Piotroski F-Score Chart

Acer Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 5.00 4.00 2.00 7.00 4.00

Acer Medical Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 0.00 7.00 0.00 4.00

ROCO:6857 vs VEEV, BTSG, TEM: Piotroski F-Score Comparison

For the Health Information Services subindustry, Acer Medical's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acer Medical Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Acer Medical's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Acer Medical's Piotroski F-Score falls into.


ROCO:6857
52GF Score
Acer Medical Inc ROCO:6857
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was NT$-29.69 Mil.
Cash Flow from Operations was NT$-24.65 Mil.
Revenue was NT$60.05 Mil.
Gross Profit was NT$37.50 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (226.893 + 207.227) / 2 = NT$217.06 Mil.
Total Assets at the begining of this year (Dec24) was NT$226.89 Mil.
Long-Term Debt & Capital Lease Obligation was NT$0.00 Mil.
Total Current Assets was NT$200.41 Mil.
Total Current Liabilities was NT$42.30 Mil.
Net Income was NT$-27.36 Mil.

Revenue was NT$50.16 Mil.
Gross Profit was NT$31.67 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (259.427 + 226.893) / 2 = NT$243.16 Mil.
Total Assets at the begining of last year (Dec23) was NT$259.43 Mil.
Long-Term Debt & Capital Lease Obligation was NT$0.00 Mil.
Total Current Assets was NT$220.89 Mil.
Total Current Liabilities was NT$32.30 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Acer Medical's current Net Income (TTM) was -29.69. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Acer Medical's current Cash Flow from Operations (TTM) was -24.65. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-29.686/226.893
=-0.130837

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-27.364/259.427
=-0.10547861

Acer Medical's return on assets of this year was -0.130837. Acer Medical's return on assets of last year was -0.10547861. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Acer Medical's current Net Income (TTM) was -29.69. Acer Medical's current Cash Flow from Operations (TTM) was -24.65. ==> -24.65 > -29.69 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=0/217.06
=0

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=0/243.16
=0

Acer Medical's gearing of this year was 0. Acer Medical's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=200.409/42.303
=4.73746543

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=220.893/32.302
=6.83836914

Acer Medical's current ratio of this year was 4.73746543. Acer Medical's current ratio of last year was 6.83836914. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Acer Medical's number of shares in issue this year was 15.226. Acer Medical's number of shares in issue last year was 15.226. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=37.503/60.054
=0.62448796

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=31.672/50.157
=0.63145722

Acer Medical's gross margin of this year was 0.62448796. Acer Medical's gross margin of last year was 0.63145722. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=60.054/226.893
=0.26467983

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=50.157/259.427
=0.19333762

Acer Medical's asset turnover of this year was 0.26467983. Acer Medical's asset turnover of last year was 0.19333762. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+1+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Acer Medical has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Acer Medical (ROCO:6857) has a Piotroski F-Score of 4 as of Jul. 02, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Acer Medical and its competitors. This is near median its historical median of 4.00. Over the past decade, Acer Medical's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Acer Medical ranks #440 out of 651 companies in the Healthcare Providers & Services industry, placing it in the top 67.6%.
Is Acer Medical's Piotroski F-Score too high?
Acer Medical's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. Acer Medical's value of 4 is 20% below this industry median. Based on the distribution chart, Acer Medical ranks #440 out of 651 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Acer Medical has a GF Score™ of 52/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Acer Medical's Piotroski F-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Acer Medical ranks #440 out of 651 companies for Piotroski F-Score. This places Acer Medical in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Acer Medical's value of 4 is 20% below this benchmark. Historically, Acer Medical's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Acer Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 651 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acer Medical's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Acer Medical and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acer Medical's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acer Medical stock overvalued right now?
Based on GuruFocus' analysis, Acer Medical (ROCO:6857) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$262.01, compared to a current price of NT$93.00 — trading 64.5% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Healthcare Providers & Services industry median of 5.00. Acer Medical's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Acer Medical (ROCO:6857), the current Piotroski F-Score is 4 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Acer Medical (ROCO:6857) Overvalued in 2026?

Based on GuruFocus' analysis, Acer Medical stock appears to be undervalued. The current stock price of NT$93.00 is trading 64.5% below its estimated GF Value™ of NT$262.01. GuruFocus considers Acer Medical to be Significantly Undervalued.

Key valuation signals for ROCO:6857:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: NT$262.01 vs. price of NT$93.00 (64.5% below fair value)
  • GF Score™: 52/100 with 4 warning signs
  • Industry Position: 20% below the Healthcare Providers & Services median (#440 of 651)

No single metric tells the full story. See the ROCO:6857 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Acer Medical Business Description

Address Xintai 5th Road, 7th Floor, No. 86, Section 1, Xizhi District, New Taipei, TWN
Acer Medical Inc focuses on improving human health and well-being through artificial intelligence. It focuses on applying artificial intelligence and large data to the area of healthcare. Acer Medical is capable of designing, developing, commercializing, as well as implementing AI solutions in medical institutions.
52GF Score

Get the complete analysis for ROCO:6857

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$93.00
Price
NT$262.01
GF Value